Top Markets
Coin of the day
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
주식 순위 #39037
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
주가
$0.38
마지막 동기화: 2023-09-01
시가총액
$677.16K
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Aceragen, Inc. (ACGN)

카테고리

Aceragen, Inc. (ACGN)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Aceragen, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Aceragen, Inc.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE